Market reactionShares fell 11% on Nov 5.
Kyverna is a clinical-stage company developing a cell therapy for stiff person syndrome, a rare autoimmune condition, and its lead candidate is not yet approved.
Miv-cel's single-arm KYSA-8 results support durable benefit in stiff person syndrome and an FDA-aligned BLA submission path. The rolling filing targets completion in Q4 2026; approval remains the central investment question. Management expects $199.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, plus available Oxford loan draws, to fund operations into 2028. Generalized myasthenia gravis remains a separate opportunity requiring randomized Phase 3 confirmation.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The SPS evidence supports an FDA approval path
Is the full SPS BLA submitted and accepted for FDA review?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Durable SPS benefit supports miv-cel's filing path; FDA approval remains decisive
KYSA-8 met every endpoint; BLA rolling submission underway for SPS, but single-arm data must clear FDA's approvability bar
KYTX's thesis rests on whether FDA will approve the first CAR-T for autoimmune disease and whether KYV-101 can scale commercially in SPS
$100M public equity offering priced
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Mivocabtagene autoleucel (miv-cel)
Disease areas: Kidney diseases, Neuromuscular diseases, Neurology and pain, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
14 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.